Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG

Leukemia

Volumn 13, Issue 5, 1999, Pages 786-791

  Byrne, J L ^a   Dasgupta, E ^a   Pallis, M ^a   Turzanski, J ^a   Forman, K ^b   Mitchell, D ^c   Haynes, A P ^a   Russell, N H ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

Author keywords

ALL; Allogeneic transplantation; AML; FLAG; MDR

Indexed keywords

CYTARABINE; FLUDARABINE; GLYCOPROTEIN P; IDARUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOGENETICS; DONOR; FEMALE; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; SIBLING; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

EID: 0033017902     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401406     Document Type: Article

References (26)

1. Estey E. Treatment of refractory AML. Leukemia 1996; 10: 932-936.
2. Sierra J, Storer B, Hansen J, Bjerke J. Transplantation of marrow cells from unrelated donors for treatment of high risk acute leukaemia: the effect of leukaemic burden, donor HLA-matching and marrow cell dose. Blood 1997; 89: 4226-4235.
3. Kern W, Aul C, Maschmeyer G, Schonrock Nabulsi R, Ludwig W, Bartholomaus A, Bettelheim P, Wormann B, Buchner T, Hiddemann W. Superiority of high dose over intermediate dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomised comparison. Leukemia 1998; 12: 1049-1055.
4. Gandhi V, Estey E, Keating M. Synergistic combination of fludarabine and Ara-C for AML therapy. Blood 1991; 78 (Suppl. 1): 52a.
5. Rayappa C, McCulloch E. A cell-culture model for the treatment of acute myeloblastic leukemia with fludarabine and cytosine-arabinoside. Leukemia 1993; 7: 992-999.
6. Gandhi V, Estey E, Du M, Nowak B, Keating M, Plunkett W. Modulation of the cellular-metabolism of cytarabine and fludarabine by granulocyte colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res 1995; 1: 169-178.
7. Tosi P, Visani G, Ottaviani E, Manfroi S, Zinzani P, Tura S. Fludarabine plus Ara-C+G-CSF - cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia 1994; 8: 2076-2082.
8. Visani G, Tosi P, Zinzani P, Manfroi S, Ottaviani E, Testoni N, Clavio M, Cennachi A, Gamberi B, Carrara P, Gobbi M, Tura S. FLAG (fludarabine plus high-dose cytarabine plus G-CSF) - an effective and tolerable protocol for the treatment of poor-risk acute myeloid leukemias. Leukemia 1994; 8: 1842-1846.
9. Parker J, Pagliuca A, Mijovic A, Cullis J, Czepulkowski B, Rassam S, Samartunga I, Grace R, Gover P, Mufti G. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-Ida) for the treatment of poor risk myelodysplastic syndromes and acute myeloblastic leukaemia. Br J Haematol 1997; 99: 939-944.
10. Nokes T, lohnson S, Harvey D, Goldstone A. FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myeloblastic syndromes. Leuk Lymphoma 1997; 27: 93-101.
11. Huhmann I, Watzke H, Geissler H, Gisslinger H, Jager U, Knobl P, Pabinger I, Korninger L, Mannhalter C, Mitterbauer G, Schwarzinger I, Kalhs P, Haas O, Lechner K. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute leukemia). Ann Haematol 1996; 73: 265-271.
12. Estey E, Kantarjian H, O'Brien S, Kornblau S, Andreeff M, Beran M, Pierce S, Keating M. High remission rate, short remission duration in patients with refractory-anemia with excess blasts (RAEB) in transformation (RAEBt) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cyto Mol Ther 1995; 1: 21-28.
13. Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, Gatti A, Cerri R, Celesti L, Vallebella E, Sessarego M, Patrone F, Ghio R, Damasio E, Gobbi M. High efficiency of fludarabine containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 1996; 81: 513-520.
14. Pallis M, Turzanski J, Langabeer S, Russell NH. Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts. In: Kaspers G, Veerman A (eds). Proceedings of the Third International Symposium on Drug Resistance in Leukaemia and Lymphoma. Plenum: New York, 1998 (in press).
15. Borovitz M, Guenther K, Shults B, Stelzer G. Immunophenotyping of acute leukaemia by flow cytometric analysis. Am J Clin Pathol 1993; 100: 534-540.
16. Carella AM, Carlier P, Pungolino E, Resegotti L, Liso V, Stasi R, Montillo M, Iacopino P, Mirto S, Pagano L, Leoni F, Martelli FM, Diraimondo F, Porcellini A, Deriu L, Nosai AM, Cimino R, Mandelli F. Idarubicin in combination with intermediate dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia 1993; 7: 196-199.
17. Kern W, Aul C, Maschmeyer G, Schonrock Nabulsi R, Ludwig WD, Bartholomaus A, Bettelheim P, Wormann B, Buchner T, Hiddemann W. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high risk acute myeloid leukemia: results of an age-adjusted prospective randomised comparison. Leukemia 1998; 12: 1049-1055.
18. Tafuri A, Defelice L, Petrucci M, Mascolo M, Ricciardi M, Ciliberti C, Martelli M, Petti M. Multidrug resistance expression and proliferative studies in poor risk acute myeloid leukaemia treated with the FLAG (G-CSF plus fludarabine and Ara-C) regimen. Cyto Mol Ther 1995; 1: 301-307.
19. Keating M, O'Brien S, Robertson L, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Yingyang L, Gandhi V, Estey E, Plunkett W. The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma 1994; 14 (Suppl. 2): 11-16.
20. Montillo M, Tedeschi A, Centurioni R, Leoni P. Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony stimulating factor (FLAG-G-CSF). Leuk Lymphoma 1997; 25: 579-583.
21. Visani G, Tosi P, Zinzani P, Manfroi S, Ottaviani E, Cenacchi A, Carrara P, Clavio M, Gobbi M, Tura S. FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukaemia with myeloid antigen expression - in vitro and in vivo effects. Eur J Haematol 1996; 56: 308-312.
22. Zhou D, Zittoun R, Marie J. Expression of multidrug resistance associated protein (MRP) and multidrug resistance (MDR-1) genes in acute myeloid leukemia. Leukemia 1995; 9: 1661-1666.
23. van den Heuvel Eibrink M, van der Holt B, te Booekhorst P, Pieters R, Schoester M, Lowenberg B, Sonneveld P. MDR-1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. Br J Haematol 1997; 99: 76-83.
24. Wood P, Burgess R, Macgregor R, Yin J. P-glycoprotein expression on acute myeloid leukemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 1994; 87: 509-514.
25. Finke J, Labopin M, Ruutu T, Bunjes D, Vemant JP, Russell NH, Greinix HT, Ringden O, Frassoni F. Unrelated donor transplantation in adult patients with acute leukemias: EBMT data. Bone Marrow Transplant 1999 (in press).
26. Sierra J, Storer B, Hansen J, Bjerke J. Transplantation of marrow cells from unrelated donors for treatment of high risk acute leukaemia: the effect of leukaemic burden, donor HLA-matching and marrow cell dose. Blood 1997; 89: 4226-4235.